Gland PharmaNSE:GLAND -0.49%83 ROA % is 11.72% as of Mar. 2026, which is 7% above its 10-year median of 10.96. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,125.65 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Gland Pharma ranks better than 79.03% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Gland Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹14,667 Mil.
Gland Pharma's average Total Assets over the quarter that ended in Mar. 2026 was ₹125,108 Mil. Therefore, Gland Pharma's annualized ROA % for the quarter that ended in Mar. 2026 was 11.72%.
The historical rank and industry rank for Gland Pharma's ROA % or its related term are showing as below:
NSE:GLAND'
s ROA % Range Over the Past 10 Years
Min: 6.38 Med: 10.96 Max: 20.31
Current: 8.67
During the past 9 years, Gland Pharma's highest ROA % was 20.31%. The lowest was 6.38%. And the median was 10.96%.
NSE:GLAND's ROA % is ranked better than 79.03% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs NSE:GLAND: 8.67
Gland Pharma (NSE:GLAND) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Gland Pharma ROA % Related Terms
Gland Pharma ROA % Historical Data
* Premium members only.
The historical data trend for Gland Pharma's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's ROA % distribution charts can be found below:
* The bar in red indicates where Gland Pharma's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Gland Pharma (NSE:GLAND) has a ROA % of 11.72% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Gland Pharma and its competitors. This is near median its historical median of 10.96. Over the past decade, Gland Pharma's ROA % has ranged from 6.38 to 20.31. According to the industry distribution chart, Gland Pharma ranks #211 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Gland Pharma's ROA % too high?
Gland Pharma's current ROA % of 11.72% is near median its 10-year median of 10.96. Over the past 10 years, this metric has ranged from a low of 6.38 to a high of 20.31. The Drug Manufacturers industry median ROA % is 2.69. Gland Pharma's value of 11.72% is 336.5% above this industry median. Based on the distribution chart, Gland Pharma ranks #211 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #211 out of 1006 companies for ROA %. This places Gland Pharma in the top 21% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. Gland Pharma's value of 11.72% is 336.5% above this benchmark. Historically, Gland Pharma's own ROA % has ranged from 6.38 to 20.31 over the past decade. While the company's 10-year median is 10.96 vs. the industry median of 2.69, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current ROA % of 11.72% is 336.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current ROA % is 11.72%, which is near median its own 10-year median of 10.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,125.65, compared to a current price of ₹2,314.80 — trading 8.9% above its estimated fair value. The current ROA % is 11.72%, which is near median its 10-year median of 10.96 and 336.5% above the Drug Manufacturers industry median of 2.69. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current ROA % is 11.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,125.65.
GuruFocus considers Gland Pharma to be Fairly Valued.
Key valuation signals for NSE:GLAND:
ROA %: 11.72% (near median its 10-year median of 10.96)
GF Value™: ₹2,125.65 vs. price of ₹2,314.80 (8.9% above fair value)
Industry Position: 336.5% above the Drug Manufacturers median (#211 of 1006)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score
Get the complete analysis for NSE:GLAND
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
